Frontiers in Virology (Apr 2022)
Highly Efficient Autologous HIV-1 Isolation by Coculturing Macrophage With Enriched CD4+ T Cells From HIV-1 Patients
- Cristina Xufré,
- Tanía González,
- Tanía González,
- Lorna Leal,
- Lorna Leal,
- Charles M. Trubey,
- Jeffrey D. Lifson,
- José María Gatell,
- José Alcamí,
- José Alcamí,
- José Alcamí,
- Núria Climent,
- Núria Climent,
- Felipe García,
- Felipe García,
- Sonsoles Sánchez-Palomino,
- Sonsoles Sánchez-Palomino
Affiliations
- Cristina Xufré
- AIDS Research Group, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain
- Tanía González
- AIDS Research Group, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain
- Tanía González
- Centro de Investigación Biomédica en Red (CIBER) of Infectious Diseases, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
- Lorna Leal
- AIDS Research Group, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain
- Lorna Leal
- Infectious Diseases Service, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
- Charles M. Trubey
- AIDS and Cancer Virus Program Inc., Frederick National Laboratory Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Frederick, MD, United States
- Jeffrey D. Lifson
- AIDS and Cancer Virus Program Inc., Frederick National Laboratory Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Frederick, MD, United States
- José María Gatell
- AIDS Research Group, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain
- José Alcamí
- AIDS Research Group, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain
- José Alcamí
- Centro de Investigación Biomédica en Red (CIBER) of Infectious Diseases, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
- José Alcamí
- AIDS Immunopathology Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain
- Núria Climent
- AIDS Research Group, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain
- Núria Climent
- Centro de Investigación Biomédica en Red (CIBER) of Infectious Diseases, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
- Felipe García
- Centro de Investigación Biomédica en Red (CIBER) of Infectious Diseases, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
- Felipe García
- Infectious Diseases Service, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
- Sonsoles Sánchez-Palomino
- AIDS Research Group, Institut d’Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain
- Sonsoles Sánchez-Palomino
- Centro de Investigación Biomédica en Red (CIBER) of Infectious Diseases, Centro de Investigación Biomédica en Red de Enfermedades Infecciosas, (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
- DOI
- https://doi.org/10.3389/fviro.2022.869431
- Journal volume & issue
-
Vol. 2
Abstract
We described a novel HIV autologous isolation method based in coculturing macrophages and CD4+T-cell-enriched fractions from peripheral blood collected from antiretroviral-treated (ART) HIV patients. This method allows the isolation of high viral titers of autologous viruses, over 1010HIV RNA copies/ml, and reduces the time required to produce necessary amounts for virus for use as antigens presented by monocyte-derived myeloid cells in HIV therapeutic vaccine approaches. By applying these high titer and autologous virus produced in the patient-derived cells, we intended to elicit a boost of the immunological system response in HIV therapeutic vaccines in clinical trials.
Keywords
- autologous HIV immunogen
- HIV isolation
- HIV therapeutic vaccine
- CD4+ T cells
- coculture
- monocyte-derived macrophages (MDM)
